Although expression of non鈥攑rotein-coding RNA (ncRNA) can be altered in human cancers, their functional relevance is unknown. Ultraconserved regions are ... C Braconi,N Valeri,T Kogure,... - 《Proceedings of the National Academy of Sciences of the United States of America》 被引量: 361...
结果:与EGFR(rs884419)基因型为AA和AG的变异组患者相比,基因型为GG的正常组患者在初诊时为M1期的占比更高(65.3%vs84.2%,P<0.05)。EGFR(rs884419)基因多态性与确诊时年龄、确诊时前列腺特异性抗原、转移负荷及Gleason评分无相关性(...
Non-AGA患者则要求EGFR/ALK阴性,且没有已知的ROS1、NTRK、BRAF、METex14、RET阳性变异,既往接受过1-2线含铂化疗和免疫治疗(联合或序贯均可)。 在整体研究人群中,两组的无进展生存期(PFS)曲线明显分离,Dato-DXd相较于多西他赛显著改善...
Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort studyOtto ManninenLaura PuuniemiSanna IivanainenMartti ArffmanRiitta KaarteenahoJussi P. Koivunen
The cell signaling factors EGFR, EphA2, and Ephexin1 are associated with lung and colorectal cancer and play an important role in tumorigenesis. Although the respective functional roles of EGFR and EphA2 are well known, interactions between these protein
The discovery of mutated oncogenes has changed the standard approach in advanced non-small cell lung cancer (NSCLC) patients and opened up a new era for the development of personalized treatment for those patients with sensitizing mutation of the Epidermal Growth Factor Receptor (EGFR). Nevertheless...
图3.EGFR第20外显子的结构。在EGFR第20外显子中,最常见的插入突变位点位于c-螺旋结构域后面的环中,特别是在AA767和AA775之间(近环:AA767-772;远环:AA773-775) 临床常用的EGFR ex20ins检测方法包括PCR法、Sanger测序法和NGS,PCR只能对已知的突变亚型进行检测,易漏检,在EGFR ex20ins等分子异质性突变检测方面...
Although one of the functions of non-histone pro- tein methylation is its effect on the subcellular localization of proteins30, our results did not support such an effect of WHSC1L1-mediated K721 EGFR mono-methylation (Supplementary Figure 5). Specifically, nuclear/cyto- plasmic fractionation...
[1]Sun YP,Xiao ZK, et al. Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.2024 AS...
6.Shi Y, Chen G, Wang X,et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre...